NO20021717L - Heterosyklisk natrium/proton utvekslingsinhibitorer og metode - Google Patents
Heterosyklisk natrium/proton utvekslingsinhibitorer og metodeInfo
- Publication number
- NO20021717L NO20021717L NO20021717A NO20021717A NO20021717L NO 20021717 L NO20021717 L NO 20021717L NO 20021717 A NO20021717 A NO 20021717A NO 20021717 A NO20021717 A NO 20021717A NO 20021717 L NO20021717 L NO 20021717L
- Authority
- NO
- Norway
- Prior art keywords
- proton exchange
- exchange inhibitors
- heterocyclic
- sodium
- heterocyclic sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15875599P | 1999-10-12 | 1999-10-12 | |
PCT/US2000/027461 WO2001027107A2 (fr) | 1999-10-12 | 2000-10-02 | Inhibiteurs heterocycliques d'echange sodium / protons et procedes a cet effet |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20021717D0 NO20021717D0 (no) | 2002-04-11 |
NO20021717L true NO20021717L (no) | 2002-06-10 |
Family
ID=22569562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021717A NO20021717L (no) | 1999-10-12 | 2002-04-11 | Heterosyklisk natrium/proton utvekslingsinhibitorer og metode |
Country Status (26)
Country | Link |
---|---|
US (2) | US6887870B1 (fr) |
EP (1) | EP1224183B1 (fr) |
JP (1) | JP2003527331A (fr) |
KR (1) | KR20020038818A (fr) |
CN (1) | CN1468232A (fr) |
AR (1) | AR026023A1 (fr) |
AT (1) | ATE314364T1 (fr) |
AU (1) | AU7859600A (fr) |
BR (1) | BR0014725A (fr) |
CA (1) | CA2388813A1 (fr) |
CO (1) | CO5251416A1 (fr) |
DE (1) | DE60025245T2 (fr) |
DK (1) | DK1224183T3 (fr) |
ES (1) | ES2254236T3 (fr) |
HK (1) | HK1045691A1 (fr) |
HU (1) | HUP0300195A3 (fr) |
IL (1) | IL148517A0 (fr) |
MX (1) | MXPA02003626A (fr) |
NO (1) | NO20021717L (fr) |
NZ (1) | NZ517668A (fr) |
PE (1) | PE20011001A1 (fr) |
PL (1) | PL366131A1 (fr) |
RU (1) | RU2002111867A (fr) |
TR (1) | TR200201014T2 (fr) |
WO (1) | WO2001027107A2 (fr) |
ZA (1) | ZA200202479B (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US7217701B2 (en) | 2001-10-11 | 2007-05-15 | Katsuhiko Mikoshiba | Intracellular calcium concentration increase inhibitors |
WO2003045383A1 (fr) * | 2001-11-26 | 2003-06-05 | Arachnova Therapeutics Ltd. | Utilisation d'activateurs des ppar dans le traitement de fibrose pulmonaire |
AU2003263393A1 (en) * | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
JP2006506379A (ja) | 2002-10-23 | 2006-02-23 | グレンマーク・ファーマシューティカルズ・リミテッド | 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物:その調製方法およびそれらを含む医薬組成物 |
DE60321593D1 (de) | 2002-11-18 | 2008-07-24 | Novartis Ag | Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron |
ATE374766T1 (de) * | 2003-01-14 | 2007-10-15 | Arena Pharm Inc | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
EP1927594A1 (fr) * | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | Dérivés d'aryle et d'hétéroaryle 1,2,3-trisubstitués en tant que modulateurs du métabolisme et la prévention et le traitement de maladies liées à celui-ci, telles que le diabète et l'hyperglycémie |
PT1620429E (pt) | 2003-04-11 | 2009-04-28 | Glenmark Pharmaceuticals Sa | Novos compostos heterocíclicos úteis para o tratamento de perturbações inflamatórias e alérgicas: processo para a sua preparação e composições farmacêuticas que os contêm |
EP1862181A3 (fr) * | 2003-04-11 | 2010-09-15 | High Point Pharmaceuticals, LLC | Polythérapie utilisant un inhibiteur de la 11B-hydroxystéroïde déshydrogénase de type 1 et agent anti-hypertensif pour le traitement du syndrome métabolique et maladies et troubles associés |
AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
EP1638947B1 (fr) * | 2003-05-29 | 2010-08-04 | Merck Sharp & Dohme Corp. | Derives de triazole utiles comme inhibiteurs de la 11-beta hydroxysteroide deshydrogenase-1 |
GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
DK1648878T3 (da) | 2003-07-24 | 2009-08-10 | Euro Celtique Sa | Piperidinforbindelser og farmaceutiske sammensætninger, som indeholder dem |
WO2005047268A2 (fr) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Compositions de pyrimidine substituee et procedes d'utilisation associes |
WO2005090282A1 (fr) * | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Composes modulateurs de recepteur d'androgenes et procedes |
GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
CA2583497A1 (fr) | 2004-10-13 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | Procede de preparation de n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide |
US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
UA88795C2 (ru) | 2004-12-17 | 2009-11-25 | Гленмарк Фармасьютікалс С.А. | Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений |
MX2007014053A (es) | 2005-05-13 | 2008-02-05 | Lilly Co Eli | N-arilpirrolidinas substituidas como moduladores selectivos de receptor de androgeno. |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
KR20090130422A (ko) | 2007-04-27 | 2009-12-23 | 퍼듀 퍼머 엘피 | 통증 치료에 유용한 치료제 |
PL2142529T3 (pl) * | 2007-04-27 | 2014-06-30 | Purdue Pharma Lp | Antagoniści trpv1 i ich zastosowania |
DK2164825T3 (da) * | 2007-06-05 | 2014-07-14 | Sanofi Sa | Di(hetero)arylcyclohexanderivater, deres fremstilling, deres anvendelse og terapeutiske præparater, der omfatter disse |
GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
WO2018129556A1 (fr) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal |
US8921373B2 (en) | 2010-06-22 | 2014-12-30 | Shionogi & Co., Ltd. | Compounds having TRPV1 antagonistic activity and uses thereof |
CA2812061A1 (fr) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies |
GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
SG10201604682VA (en) | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
MY185061A (en) | 2011-06-22 | 2021-04-30 | Shionogi & Co | Trpv1 antagonists including dihydroxy substituent and uses thereof |
US9394293B2 (en) | 2011-08-10 | 2016-07-19 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
US8765959B2 (en) * | 2011-12-23 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Piperidine derivatives |
AR090880A1 (es) * | 2012-04-30 | 2014-12-10 | Janssen R & D Ireland | Derivados de pirimidina |
BR112014026828A2 (pt) * | 2012-05-30 | 2017-06-27 | Hoffmann La Roche | compostos de triazolo como inibidores de pde10 |
WO2014010748A1 (fr) * | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Dérivé de cyclopropane présentant une activité inhibitrice de bace1 |
JP6009851B2 (ja) * | 2012-07-27 | 2016-10-19 | 日本曹達株式会社 | 1h−テトラゾール誘導体の製造方法 |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR20230132619A (ko) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CA3002551A1 (fr) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1 |
ES2901197T3 (es) | 2016-03-22 | 2022-03-21 | Merck Sharp & Dohme | Moduladores alostéricos de los receptores nicotínicos de la acetilcolina |
AU2017257377B2 (en) * | 2016-04-29 | 2022-06-23 | Iomet Pharma Ltd. | Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase |
EP3565811A1 (fr) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibiteurs d'antiport à médiation par nhe |
AU2018205400B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
WO2018149940A1 (fr) | 2017-02-17 | 2018-08-23 | Quimica Sintetica, S. A. | Procédé de préparation de dihydrobenzofuranes enrichis de manière énantiomérique et composés intermédiaires obtenus durant le procédé |
WO2018224455A1 (fr) | 2017-06-07 | 2018-12-13 | Basf Se | Dérivés de cyclopropyle substitués |
WO2018234488A1 (fr) | 2017-06-23 | 2018-12-27 | Basf Se | Dérivés de cyclopropyle substitués |
BR112020002322A2 (pt) | 2017-08-04 | 2020-09-01 | Ardelyx, Inc. | derivados de ácido glicirretinínico para o tratamento de hipercalemia |
WO2019121143A1 (fr) | 2017-12-20 | 2019-06-27 | Basf Se | Dérivés de cyclopropyle substitués |
AU2020218255A1 (en) | 2019-02-07 | 2021-09-09 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
WO2020237096A1 (fr) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combinaison pour baisser le phosphate sérique chez un patient |
JP2022549601A (ja) | 2019-09-18 | 2022-11-28 | 武田薬品工業株式会社 | ヘテロアリール血漿カリクレインインヒビター |
PT4031547T (pt) | 2019-09-18 | 2024-08-27 | Takeda Pharmaceuticals Co | Inibidores de calicreína plasmática e utilizações dos mesmos |
WO2022086920A1 (fr) * | 2020-10-20 | 2022-04-28 | Blacksmith Medicines, Inc. | Inhibiteurs de la protéine de type glutaminyl-peptide cyclotransférase (qpctl) et leurs utilisations |
JP2024510503A (ja) * | 2021-03-17 | 2024-03-07 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1206498B (it) | 1983-07-18 | 1989-04-27 | Angeli Inst Spa | Derivati amidinici del4-fenilmidazolo 2-sostituto processi per la loro preparazione e loro uso farmaceutico. |
FR2579596B1 (fr) * | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
IT1201454B (it) * | 1985-08-19 | 1989-02-02 | Boehringer Biochemia Srl | 1,4-diidropiridine-2-sostituite |
US4663473A (en) * | 1986-08-25 | 1987-05-05 | The United States Of America As Represented By The Secretary Of The Army | Isocyanates from oxalyl chloride and amines |
FR2674855B1 (fr) * | 1991-04-03 | 1994-01-14 | Synthelabo | Derives de piperidine, leur preparation et leur application en therapeutique. |
US5380858A (en) * | 1992-04-01 | 1995-01-10 | The University Of Toledo | Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists |
FR2696177B1 (fr) * | 1992-09-28 | 1995-05-12 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
ZA97288B (en) * | 1996-01-15 | 1998-07-14 | Janssen Pharmaceutica Nv | Angiogenesis inhibiting pyridazinamines |
FR2765221B1 (fr) | 1997-06-25 | 1999-07-30 | Synthelabo | Derives de 4-[(1h-imidazol-4-yl)piperidin-1-yl]anilide, leur preparation et leur application en therapeutique |
FR2765580B1 (fr) | 1997-07-01 | 1999-08-06 | Synthelabo | Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique |
FR2772377B1 (fr) * | 1997-12-12 | 2000-01-07 | Synthelabo | Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique |
US6011059A (en) * | 1997-12-24 | 2000-01-04 | Bristol-Myers Squibb Company | Acyl guanidine sodium/proton exchange inhibitors and method |
EP1136489A1 (fr) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Dérivés de 2-[pipéridinyl]pyrimidinone |
-
2000
- 2000-09-25 US US09/669,298 patent/US6887870B1/en not_active Expired - Lifetime
- 2000-10-02 KR KR1020027004653A patent/KR20020038818A/ko not_active Application Discontinuation
- 2000-10-02 CA CA002388813A patent/CA2388813A1/fr not_active Abandoned
- 2000-10-02 IL IL14851700A patent/IL148517A0/xx unknown
- 2000-10-02 JP JP2001530325A patent/JP2003527331A/ja not_active Withdrawn
- 2000-10-02 DE DE60025245T patent/DE60025245T2/de not_active Expired - Lifetime
- 2000-10-02 WO PCT/US2000/027461 patent/WO2001027107A2/fr active IP Right Grant
- 2000-10-02 HU HU0300195A patent/HUP0300195A3/hu unknown
- 2000-10-02 MX MXPA02003626A patent/MXPA02003626A/es unknown
- 2000-10-02 AU AU78596/00A patent/AU7859600A/en not_active Abandoned
- 2000-10-02 DK DK00968723T patent/DK1224183T3/da active
- 2000-10-02 TR TR2002/01014T patent/TR200201014T2/xx unknown
- 2000-10-02 CN CNA008140626A patent/CN1468232A/zh active Pending
- 2000-10-02 ES ES00968723T patent/ES2254236T3/es not_active Expired - Lifetime
- 2000-10-02 AT AT00968723T patent/ATE314364T1/de active
- 2000-10-02 NZ NZ517668A patent/NZ517668A/en unknown
- 2000-10-02 BR BR0014725-7A patent/BR0014725A/pt not_active Expired - Fee Related
- 2000-10-02 PL PL00366131A patent/PL366131A1/xx unknown
- 2000-10-02 EP EP00968723A patent/EP1224183B1/fr not_active Expired - Lifetime
- 2000-10-02 RU RU2002111867/04A patent/RU2002111867A/ru not_active Application Discontinuation
- 2000-10-10 CO CO00077054A patent/CO5251416A1/es not_active Application Discontinuation
- 2000-10-10 PE PE2000001081A patent/PE20011001A1/es not_active Application Discontinuation
- 2000-10-12 AR ARP000105372A patent/AR026023A1/es not_active Application Discontinuation
-
2002
- 2002-03-27 ZA ZA200202479A patent/ZA200202479B/xx unknown
- 2002-04-11 NO NO20021717A patent/NO20021717L/no not_active Application Discontinuation
- 2002-09-30 HK HK02107204.5A patent/HK1045691A1/zh unknown
-
2005
- 2005-01-31 US US11/046,993 patent/US7326705B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU7859600A (en) | 2001-04-23 |
HUP0300195A2 (hu) | 2003-07-28 |
AR026023A1 (es) | 2002-12-26 |
PL366131A1 (en) | 2005-01-24 |
KR20020038818A (ko) | 2002-05-23 |
RU2002111867A (ru) | 2004-05-10 |
HK1045691A1 (zh) | 2002-12-06 |
CN1468232A (zh) | 2004-01-14 |
DK1224183T3 (da) | 2006-03-06 |
ZA200202479B (en) | 2004-10-27 |
US6887870B1 (en) | 2005-05-03 |
CA2388813A1 (fr) | 2001-04-19 |
CO5251416A1 (es) | 2003-02-28 |
IL148517A0 (en) | 2002-09-12 |
US7326705B2 (en) | 2008-02-05 |
NZ517668A (en) | 2004-09-24 |
HUP0300195A3 (en) | 2003-09-29 |
EP1224183A2 (fr) | 2002-07-24 |
PE20011001A1 (es) | 2001-11-25 |
MXPA02003626A (es) | 2003-09-22 |
BR0014725A (pt) | 2003-06-17 |
DE60025245D1 (de) | 2006-02-02 |
JP2003527331A (ja) | 2003-09-16 |
WO2001027107A2 (fr) | 2001-04-19 |
WO2001027107A3 (fr) | 2002-01-24 |
ES2254236T3 (es) | 2006-06-16 |
TR200201014T2 (tr) | 2003-01-21 |
NO20021717D0 (no) | 2002-04-11 |
ATE314364T1 (de) | 2006-01-15 |
DE60025245T2 (de) | 2006-08-24 |
EP1224183B1 (fr) | 2005-12-28 |
US20050137216A1 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20021717D0 (no) | Heterocykliske natrium/proton utvekslingsinhibitorer og metode | |
NO20014823D0 (no) | Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode | |
DK1133477T3 (da) | Substituerede benzimidazoler og deres anvendelse som parpinhibitorer | |
EE200000610A (et) | p38 heterotsüklilised inhibiitorid | |
NO20013452D0 (no) | Benzoheterocykler og deres anvendelse som MEK-inhibitorer | |
IS6385A (is) | Ný notkun og nýjar N-asabísýkló-amíð afleiður | |
NO2011002I2 (no) | Regadenoson og salter derav | |
NO20022086L (no) | Antidiabetisk formulering og fremgangsmåte | |
DK1454907T3 (da) | Quninazolin og pyridopyrmidin-derivativer | |
DE60008527D1 (de) | Zellproliferation inhibitoren | |
NO20022656L (no) | Caspaseinhibitorer og anvendelse derav | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
DK1177178T3 (da) | Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse | |
NO20012688D0 (no) | Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer | |
NO20032668D0 (no) | Gyraseinhibitorer og anvendelser derav | |
DK0925287T3 (da) | Heterocykliske metalloproteaseinhibitorer | |
DK1251848T3 (da) | Gyraseinhibitorer og anvendelse deraf | |
DK0923561T3 (da) | Heterocykliske metalloproteaseinhibitorer | |
NO20000188D0 (no) | Fremgangsmåte og anordning for sidebroenntilknytning | |
NO20022853L (no) | System og fremgangsmåte for multiprosessorforvaltning | |
DE60024101D1 (de) | Enzyminhibitoren | |
NO20010405D0 (no) | Pyrazolderivater og salter derav | |
NO20001718L (no) | Benzen-fusjonerte heterocykliske derivater og anvendelse derav | |
DK1228026T3 (da) | 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse | |
NO20000053L (no) | FremgangsmÕte til dataoverføring |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |